Clinical trial NCT03920631: Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas
Official title: MicroBLITZ: Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: B Cell Lymphomas
Keywords: B Cell Lymphomas
Microtransplantation
Nivolumab
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2019-04-19
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to find out if microtransplantation (MST) in combination with nivolumab is safe and effective in patients with relapsed or refractory B cell lymphomas.

Detailed description: This is a non-randomized, open-label, phase 1 study to assess the safety of nivolumab (OPDIVO™, also referred to as BMS-936558, MDX1106, and ONO-4538) in combination with microtransplantation (MST) in patients ≥ 18 years of age with relapsed or refractory B cell lymphomas. A conventional cohorts-of-3 dose-escalation phase I design will be used to determine the optimal dosing strategy of nivolumab in combination with MST. The safety of microtransplantation without nivolumab will be evaluated at the first dose level. If significant, unexpected toxicity is observed at Dose Levels 2 or 3, subsequent cohorts will switch to the alternate dosing schedule to evaluate the safety of dose-reduced nivolumab. After determination of the maximum tolerated dose level, patients will be recruited into an expansion cohort at that level.

Eligibility criteria: Inclusion Criteria:

1. Patients with relapsed/refractory B cell lymphomas of the following subtypes:

   * Diffuse large B-cell lymphoma (DLBCL)
   * High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 translocations (DHL/THL)
   * B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma (GZL)
   * Primary mediastinal large B-cell lymphoma (PMBCL)
   * Mantle cell lymphoma (MCL)
   * Follicular lymphoma (FL)
   * Marginal zone lymphoma (MZL)
   * Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM)
   * Hodgkin lymphoma (HL)
2. Ability to provide written informed consent for the protocol and understand the investigational nature of the study.
3. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other procedures.
4. Age ≥ 18 years old.
5. Eastern Cooperative Oncology Group performance status of ≤ 2.
6. Evidence of at least one measurable lesion on imaging, defined as nodes/nodal masses \> 1.5 cm, extranodal masses \>1.0 cm or PET avid lesions consistent with lymphoma.
7. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, and men who are sexually active must use effective methods of contraception from the time of enrollment to 1 month after last therapy administered as part of the protocol.
8. Must have biopsy-proven primary refractory disease or relapsed disease after frontline therapy.
9. Adequate organ function parameters:

   1. Renal function: Creatinine clearance ≥ 45ml/min (Cockrauft-Gault Formula)
   2. Liver function:

      * AST/ALT ≤ 3x the institutional ULN.
      * Total bilirubin ≤ 2x the institutional ULN with the exception of patients with Gilbert syndrome; patients with Gilbert syndrome may be included if their total bilirubin is ≤ 3.0x ULN and direct bilirubin is ≤ 2x ULN
   3. Pulmonary function: PFTs with DLCO ≥ 40%.
   4. Cardiac function: Must have LVEF ≥ 40% confirmed by echocardiogram or MUGA scan.
   5. Bone marrow reserve without transfusion defined as:

      * Absolute neutrophil count (ANC) ≥ 1,000/mm3
      * Platelets ≥ 50,000/mm3
10. Subjects must have a potential 3-5/6 HLA-matched (A, B, DRB1) related haploidentical donor (either a first or second- degree relative) that will be evaluated for eligibility to provide hematopoietic cells for infusion.

Exclusion Criteria:

1. Prior Treatments:

   1. Prior treatment with allogeneic HSCT.
   2. Treatment with CAR-T cells within 6 months of study enrollment.
   3. Treatment with an immune checkpoint inhibitor within 3 months of study enrollment.
   4. Prior grade 3 or higher toxicities with immune checkpoint inhibitor use, excluding lymphopenia, asymptomatic amylase or lipase elevation or laboratory abnormalities that correct to grade 1 within 72 hours.
   5. Chemotherapy, radiation or surgical resection of malignancy within 2 weeks prior to the start of lymphodepleting chemotherapy (washout period).
2. Active, uncontrolled serious infection or medical or psychiatric illness, that in the investigator's opinion is likely to interfere with participation in this clinical trial.
3. Known active CNS involvement by malignancy.
4. History of seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.
5. Active replication of hepatitis B or active hepatitis C (HCV RNA positive). Those with prior disease who are PCR negative at enrollment and meet liver function eligibility criterion are eligible.
6. Known HIV positive patients.
7. Patients with unstable angina and/or myocardial infarction within 6 months prior to screening.
8. Cardiac arrhythmia not controlled with medical management, evidence of pericardial effusion on imaging that is compromising function.
9. History of a second malignancy requiring treatment at any time within the 3 years prior to study enrollment. The following are allowed within 3 years of study enrollment if subject has received definitive local therapy (i.e., surgical excision, external beam radiation, or other local therapy with curative intent): non-melanoma skin cancers, organ-confined localized prostate cancer treated with curative intent, or carcinoma in situ.
10. Active autoimmune disease, history of primary immunodeficiency, or any syndrome that requires systemic corticosteroids or immunosuppressive medications (excluding Hashimoto's thyroiditis, vitiligo, or DM type I).
11. History of solid organ transplantation.
12. Pregnant or lactating women.
13. Prisoners or those compulsorily detained.

Primary outcomes:
measure: Maximum Tolerated Dose of nivolumab in combination with Microtransplantation
timeFrame: 1.5 years
measure: Incidence of dose limiting toxicity (DLT)
timeFrame: 4 years
measure: Number of subjects experiencing AE
timeFrame: 4 years
Secondary outcomes:
measure: Overall response rate (%) is defined as the number of patients achieving a complete response or partial response as a proportion of total patients evaluable for response.
timeFrame: 2.5 years
measure: Progression-free Survival (PFS)
timeFrame: 4 years
measure: Overall Survival
timeFrame: 4 years
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University
state: North Carolina
Study officials:
affiliation: Duke Health
name: Ahmed Galal, MD
role: PRINCIPAL_INVESTIGATOR
References: